PDCD1 and neoplasm: The assessment of the tumor microenvironmental might help to identify those tumors more vulnerable to immunotherapy, as tumors with PD-1 expression and presence of tumor-infiltrating lymphocytes are most likely to experience response to anti-PD1/L1 blockage [72].